Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice

Background: The efficacy of nivolumab and atezolizumab in advanced pre-treated NSCLC was documented in prospective trials. We aim to confirm the benefits and indicate predictive factors for immunotherapy in daily practice. Methods: This study was a retrospective analysis. The median PFS and OS were...

Descripción completa

Detalles Bibliográficos
Autores principales: Knetki-Wróblewska, Magdalena, Tabor, Sylwia, Piórek, Aleksandra, Płużański, Adam, Winiarczyk, Kinga, Zaborowska-Szmit, Magdalena, Zajda, Katarzyna, Kowalski, Dariusz M., Krzakowski, Maciej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053214/
https://www.ncbi.nlm.nih.gov/pubmed/36983409
http://dx.doi.org/10.3390/jcm12062409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053214/
https://www.ncbi.nlm.nih.gov/pubmed/36983409
http://dx.doi.org/10.3390/jcm12062409

Ejemplares similares